Search Results

You are looking at 1 - 2 of 2 items for

  • Author or Editor: Karen S. Tobias x
  • Refine by Access: All Content x
Clear All Modify Search



To determine systemic and local platinum concentrations released from subcutaneously implanted cis-diamminedichloroplatinum (cisplatin)-impregnated polymethylmethacrylate (PMMA) and to evaluate systemic or local adverse reactions.


6 healthy dogs.


Cisplatin (20 mg) was inserted into PMMA that was fashioned into cylinders and placed into subcutaneous tissue chambers overlying the thorax (treated site). An empty tissue chamber was placed over the opposite side (control site). Plasma samples were obtained for platinum determination before implantation, at 3, 6, and 12 hours after implantation on day 0, and once daily on days 1, 2, 3, 7, 14, 21, and 29. At similar times on similar days, tissue chamber fluid samples also were obtained for platinum determination. Complete blood count, serum urea nitrogen and creatinine concentration determinations, and urinalyses were performed on days 1, 2, 3, 7, 14, 21, and 29. Complete necropsy was performed at conclusion of the study.


Tissue chamber platinum concentrations at the treated site were significantly greater than plasma and control site tissue chamber concentrations on days 2, 3, 7, 10. Mean plasma platinum concentration at 3 (0.735 µg/ml), 6 (0.691 µg/ml), 12 (0.534 µg/ml), 24 (0.131 µg/ml), 48 (0.2 µg/ml), 72 (0.1 µg/ml), and 158 (0.014 µg/ml) hours was significantly greater than pretreatment values (0.0 µg/ml). Plasma platinum concentration 10 days after treatment (0.011 µg/ml) did not significantly differ from pretreatment values. Local or systemic adverse reactions were not apparent.


The route of cisplatin administration was safe. Greater concentration of platinum was released locally relative to plasma concentration for an extended period. (Am J Vet Res 1999;60:280–283)

Free access
in American Journal of Veterinary Research



To determine long-term outcomes and factors associated with those outcomes in dogs with gastroesophageal intussusception (GEI).


36 dogs with GEI evaluated at 16 veterinary hospitals from January 2000 through January 2018.


Medical records of included dogs were reviewed to collect information regarding signalment, clinical signs, physical examination findings, blood work and diagnostic imaging results, surgical findings, and outcome. Factors were evaluated for associations with various outcomes.


Median age of dogs with GEI was 13.2 months, and males (72% [26/36]) and German Shepherd Dogs (33% [12/36]) were most common. Vomiting (67% [24/36]) and regurgitation (33% [12/36]) were the most common clinical signs. Ten of 36 (28%) dogs were euthanized without treatment, and 26 (72%) underwent treatment (25 surgically and 1 endoscopically). Twenty-three of the 26 (88%) treated dogs survived to discharge; median survival time was 995 days. At last follow-up, 15 of the 23 (65%) surviving dogs remained alive and 8 (35%) had died for reasons related to persistent regurgitation (n = 6) or reasons unrelated to GEI (2). Of the 10 dogs for which owners were contacted, 7 had persistent regurgitation, the severity of which was reduced through managed feedings. Dogs with acute (≤ 7 days) clinical signs or a previous diagnosis of megaesophagus were more likely to have persistent regurgitation than were dogs without these factors.


Treatment should be considered for dogs with GEI given the high rate of survival to discharge and median survival time. Although persistent regurgitation was common after treatment, a satisfactory outcome was possible with medical management, including managed feedings and medications.

Full access
in Journal of the American Veterinary Medical Association